PT  - JOURNAL ARTICLE
AU  - Philippe D. Violette
AU  - Fred Saad
TI  - Chemoprevention of Prostate Cancer: Myths and Realities
AID  - 10.3122/jabfm.2012.01.110117
DP  - 2012 Jan 01
TA  - The Journal of the American Board of Family
                Medicine
PG  - 111--119
VI  - 25
IP  - 1
4099  - http://www.jabfm.org/content/25/1/111.short
4100  - http://www.jabfm.org/content/25/1/111.full
SO  - J Am Board Fam Med2012 Jan 01; 25
AB  - Background: Prostate cancer will affect 15% to 18% of men in North America and will result in death in 3%. Established curative and palliative treatments for prostate cancer are associated with significant morbidity and cost. For these reasons, prostate cancer is an ideal target for prevention. Methods: Using MEDLINE we performed a systematic review of clinical trials that have investigated pharmaceutical or nutritional interventions for the prevention of prostate cancer. The available evidence was critically evaluated and summarized according to the strength of recommendation taxonomy. Results: Many pharmaceutical and nutritional interventions have been investigated for the prevention of prostate cancer. The strongest evidence exists to support the use of 5 α-reductase inhibitors (5-ARIs) for prevention of prostate cancer. However, the evidence is insufficient to recommend that these agents be used routinely among all men. In addition, the optimal timing or duration of 5-ARI use in not known. At present there is no suitable evidence to recommend using any specific nutritional supplement or diet to prevent prostate cancer. Conclusions: Prostate cancer prevention should not be offered systematically to all men. There may be a role for 5-ARI use among motivated men who wish to take a proactive approach to prostate cancer prevention.